Merck Confirms Data Leak in Melanoma Vaccine Trial With Moderna

The leak itself matters less than what it confirmed: the recurrence-free survival benefit held up against the disclosed figures, which lends the readout credibility even as the disclosure path raises governance questions for a late-stage program. The practical effect is on the competitive field around adjuvant melanoma, where a validated combination would reset expectations for rivals. Overall survival remains the unresolved piece — immature data with a favorable trend is not the same as demonstrated benefit, and whether that trend matures into a statistically meaningful result is the open question.